Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Debiopharm partners Ecole Polytechnique Federale de Lausanne in stem cell project

Debiopharm : 03 September, 2008  (Company News)
Debiopharm Group has signed a research project agreement with the Ecole Polytechnique Federale de Lausanne (EPFL), which is aimed at the identifying novel small molecules and peptides that interfere with pathways controlling cell fate specification.
The project, named Debio 0826, could lead to the development of potential therapeutic compounds and to the identification of new targets to fight cancer stem cells.

Following the signature of an EPFL-Debiopharm partnership on February 12, 2008 this first joint research project will be performed under the supervision of Dr Freddy Radtke, associate professor at the Swiss Institute for Experimental Cancer Research (ISREC) and Dr Gerardo Turcatti, MER, director of the Biomolecular Screening Facility (BSF), two groups at the EPFL. Debio 0826 will benefit from the multiple molecular and genetic tools generated by Dr Radtke's group over the past 10 years, as well as the expertise of Dr Turcatti in the molecular screening field.

'Targeting pathways controlling cell fate specification could generate innovative anti-cancer drugs with anti-tumoural, anti-metastatic and anti-angiogenic properties to treat tumours that are currently resistant to standard therapies,' said Kamel Besseghir, chief executive officer of Debiopharm.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo